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SUMMARY
Myelodysplastic syndromes and chronic myelomo-
nocytic leukemia are blood disorders character-
ized by ineffective hematopoiesis and progressive
marrow failure that can transform into acute leuke-
mia. The DNA methyltransferase inhibitor 5-azacyti-
dine (AZA) is the most effective pharmacological op-
tion, but only 50% of patients respond. A response
only manifests after many months of treatment and
is transient. The reasons underlying AZA resistance
are unknown, and few alternatives exist for non-
responders. Here, we show that AZA responders
have more hematopoietic progenitor cells (HPCs) in
the cell cycle. Non-responder HPC quiescence is
mediated by integrin a5 (ITGA5) signaling and their
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hematopoietic potential improved by combining AZA
with an ITGA5 inhibitor. AZA response is associated
with the induction of an inflammatory response in
HPCs in vivo. By molecular bar coding and tracking
individual clones, we found that, although AZA alters
the sub-clonal contribution to different lineages,
founder clones are not eliminated and continue to
drive hematopoiesis even in complete responders.
INTRODUCTION
Myelodysplastic syndrome (MDS) is a diverse group of hemato-
logical disorders characterized by impaired peripheral blood
cell production and abnormal bone marrow (BM) that affects
3.5–12.6 per 100,000 people per year. The incidence increases
with age and is approximately five times greater in people over
the age of 70. Patients with MDS die as a consequence of
marrow failure or progression to acute myeloid leukemia (Nimer,
2008). Chronic myelomonocytic leukemia (CMML) is a related
hematological neoplasm with features of both MDS and the
myeloproliferative neoplasms. Cytogenetic defects and muta-
tions are common in both MDS and CMML, with recurrent muta-
tions observed in the RNA splicing machinery (Yoshida et al.,
2011), cohesion complex (Kon et al., 2013), transcription factors,
signal transduction machinery, and epigenetic modifiers (Caz-
zola et al., 2013). Although some mutations have clear clinical
and prognostic implications (Bejar et al., 2011, 2014b; Itzykson
et al., 2011; Traina et al., 2014), their etiological roles are still
being elucidated.
Azacitidine (AZA) is a cytidine analog that is incorporated
into DNA and RNA (Issa and Kantarjian, 2009). In the process
of DNA methylation, DNA methyltransferases (DNMTs) become
covalently linked to DNA-incorporated AZA and degraded, lead-
ing to global DNA demethylation (Issa and Kantarjian, 2009).
Approximately half of all AZA-treated MDS or CMML patients
respond to treatment, and response is associated with improved
survival outcomes and decreased likelihood of leukemic trans-
formation (Fenaux et al., 2009; Silverman et al., 2002). The
efficacy of AZA compared with supportive care alone has been
shown in MDS (Fenaux et al., 2009) and CMML (Ade`s et al.,
2013; Costa et al., 2011). However, the dynamics of AZA
response are slow, requiring 4–6months of treatment to become
apparent. With few alternative therapeutic options for AZA non-
responders, the prognosis for such patients is consequently very
poor (Pre´bet et al., 2011). Although some clinical parameters
(Ade`s et al., 2013; Itzykson et al., 2013a) and genetic mutations
(Bejar et al., 2014a; Itzykson et al., 2011) have weak correlations
with favorable AZA response, the molecular mechanisms under-
lying primary AZA resistance are poorly understood. Further-
more, AZA response is rarely sustained, and a significant fraction
of patients who initially respond will eventually relapse within
a 2-year period, with very poor subsequent prognosis (Pre´bet
et al., 2011). The reasons for secondary AZA resistance are
also poorly understood.
Here we describe investigations that revealed that cell cycle
quiescence, primarily of hematopoietic progenitor cells (HPCs),
underpins primary AZA resistance. We show that AZA respon-
siveness is improved in vitro by combinatorially blocking integrin
a5 signaling, known to mediate cell cycle quiescence. Our dis-
coveries, therefore, not just offer a clinically useful method to
prospectively identify AZA non-responders early, thus averting
months of potentially futile therapy, but also provide one rational
avenue for developing future combination therapies to benefit
such patients. We have also identified that AZA treatment
induces an inflammatory response in vivo. Last, to shed light
on the in vivo fates of dysplastic cells upon AZA response, we
‘‘molecularly bar-coded’’ clones using somatic mutations per-
sonal to each patient, identified through exome sequencing.
We have discovered that AZA response does not alter clonal he-
matopoiesis or reduce the abundance of clones bearing driver
mutations. However, using single-colony genotyping, we have
uncovered that AZA alters the sub-clonal contribution to distinct
hematopoietic lineages.
RESULTS
Identification of Pre-treatment Gene Expression
Differences between AZA Responders and
Non-responders
Subsidized AZA access in Australia and Europe for MDS or
CMML patients is limited to those with poor prognostic scores
and high risk of transformation to acute myeloid leukemia
(AML). Prior to the availability of AZA on the Pharmaceuticals
Benefit Scheme (PBS) in Australia in 2011, we enrolled 19 pa-
tients (nine with CMML, ten with MDS; Table S1) on a compas-
sionate access program. Inclusion criteria were in line with those
stipulated for MDS or CMML patients to access AZA on the PBS
(Table S1). AZA was administered at a dose of 75 mg/m2/day
for 7 days on a 4-week cycle. The dose was increased to
100 mg/m2/day when no beneficial effect and no significant
toxicity were seen after two treatment cycles. Dose reductions
were not required. Patients who had received any prior dis-
ease-modifying agents were excluded. Blood products were
allowed, but the use of hematopoietic growth factors during
the study was prohibited.
We collected 100 mL of BM and isolated CD34+ hematopoi-
etic/stem progenitor cells (HSPCs) with high purity at distinct
stages during treatment for transcriptomic, genomic, and
matching functional analyses (Figure 1A). Twelve patients were
AZA responders, and seven were non-responders (Table S1),
according to the International Working Group criteria (Cheson
et al., 2006). We hypothesized that pre-existing molecular differ-
ences at baseline in HSPCs might drive primary AZA resistance.
To identify differentially expressed genes at pre-treatment, we
performed RNA sequencing (RNA-seq) on pre-treatment HSPCs
in a discovery cohort of 13 patients (seven responders: MDS,
n = 4 and CMML, n = 3; six non-responders: MDS, n = 4 and
CMML, n = 2; Table S2). Tissue samples from the remaining
six responders (MDS, n = 3; CMML, n = 3) were saved for
independent validation, along with samples sourced from two
independent cohorts from the United Kingdom and Sweden
(as described later). Bioinformatics analyses identified a set of
genes (n = 731; Table S3) that were differentially expressed at
false discovery rate (FDR) % 0.05 between responders and
non-responders (Figure 1B; Figure S1A). There was little overlap
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Figure 1. Identification of Pre-treatment Gene Expression Differences between AZA Responders and Non-responders
(A) Schematic depicting cycles of AZA treatment and time points of BM collection per individual. Right: the different BM sub-fractions that were collected per time
point and the analyses performed on them.
(legend continued on next page)
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between our gene set and two recently published prognostic
marker gene sets (Pellagatti et al., 2013; Figure S1B), nor any
correlation with clinical parameters (Table S4). To conclusively
rule out the possibility that gene expression differences were
simply due to some other unappreciated difference in disease
severity, we utilized a cohort of AZA-untreated MDS/RAEB-2
patients (n = 43, Oxford, United Kingdom) where transcriptome
data from HSPCs (Pellagatti et al., 2010) and survival data
were available. We dichotomized patients into putative AZA re-
sponders and non-responders based on the relative expression
of our gene set but found no differences in survival between
these two groups (Figure 1C). Comparable matched HSPC
transcriptome data and long-term survival data in AZA-untreated
CMML patients were not available, precluding identical analysis
in CMML patients. However, from available evidence, these
analyses support the alternative hypothesis that the differential
gene expression in our cohort was related to a predisposition
to respond to AZA therapy.
Pathway analyses of the upregulated genes in responders
showed significant enrichment for pathways related to cell cycle
progression (Ingenuity Pathway Analysis [IPA], see Figure 1D;
Metacore, see Figure S1C), covering all stages of the cell cycle
(Figure S2A), and DNA damage response pathways that are
inextricably linked to cell cycle passage (Branzei and Foiani,
2008; Figure 1D; Figures S1C–S2C). Gene set enrichment anal-
ysis (GSEA) also uncovered significant enrichment for a number
of cell cycle-related gene sets in responders (Figure 1E). All of
these data indicated downregulation of cell-cycle related path-
ways in the BM CD34+ HSPCs of primary AZA non-responders
prior to treatment.
Cell Cycle Quiescence of Hematopoietic Progenitors
Marks AZA Non-responders
We performed independent validation of the cell cycle differ-
ences using pre-treatment BM CD34+ HSPCs from a cohort of
54 patients from the United Kingdom (n = 14), Sweden (n = 34),
and Australia (n = 6), consisting of 33 AZA responders (MDS,
n = 28; CMML, n = 5; Table S5) and 21 non-responders (MDS,
n = 19; CMML, n = 2; Table S5). We identified a set of 20 cell cy-
cle-related genes that had significant differential expression be-
tween AZA responders and non-responders at pre-treatment
in our discovery cohort (median FDR = 0.0002; Table S3) and
that were consistently present among the top deregulated cell
cycle pathways in our IPAs (Figure 1D). Furthermore, the differ-
ential expression of just these genes was sufficient to efficiently
separate responders from non-responders in our discovery
cohort (Figure S3A). Using custom-designed real-time PCR
probes against these genes, we confirmed that the differential
expression of these genes could also identify responders from
non-responders in the validation cohort (Figure 2A) with a sensi-
tivity of 78.8% and a positive predictive value of 76.5%. Our find-
ings are consistent with the recent observation of increased
cell cycle quiescence in CMML non-responders to decitabine
therapy (Meldi et al., 2015). However, we were unable to
observe similar gene expression differences in cell cycle genes
using matched bulk unfractionated mononuclear cells (MNCs)
collected from the patients in our cohort (data not shown), high-
lighting that cell type is an important parameter that warrants
addressing in cross-cohort validation and limiting the utility of a
gene expression-based assay as a routine diagnostic tool.
To further pursue the link between cell cycle quiescence
and AZA resistance with an assay that can be performed on
unfractionated cell populations, we adapted a flow cytometry-
based method (Tehranchi et al., 2010) to measure cell cycle
parameters in matched pre-treatment MNCs from 12 patients
(six responders and six non-responders) in whom we performed
gene expression analyses as well as BM MNCs from six healthy
adult volunteers (Experimental Procedures; Figure S3B). Healthy
Lin CD34+ CD38low/ CD90+ hematopoietic stem cells (HSCs)
were mostly quiescent (the median G0, G1, and S/G2/M propor-
tions were 79.7%, 20%, and 0.7%, respectively; Figures 2B and
2C), whereas Lin CD34+ CD38+ HPCs were cycling (median
G0, G1, and S/G2/M: 20.1%, 71.8%, and 6.6%, respectively;
Figure 2C). HSCs (Lin CD34+ CD38low/ CD90+) from patients
were also mostly quiescent (median G0, responders = 81.75%,
non-responders = 77.3%, p = 0.76). However, the HPCs (Lin
CD34+ CD38+) of non-responders were markedly quiescent,
with few replicating cells (median G0, non-responders =
65.2%, responders = 46.3%, p = 0.019; median S/G2/M, non-re-
sponders = 1.24%, responders = 7.68%, p = 0.0023; Figures 2B
and 2C). These data were not only consistent with the gene
expression-based identification that CD34+ HSPCs in non-re-
sponders were quiescent but, additionally, revealed that it is
specifically the population of normally cycling CD34+ CD38+
HPCs in the BM that is quiescent in AZA non-responders.
Targeting Cell Cycle Quiescence to Overcome AZA
Resistance
We hypothesized that disruption of pathways that maintain
quiescence might restore AZA sensitivity. Within the genes that
were upregulated in AZA non-responders, we observed enrich-
ment for a number of signaling pathways, chiefly integrin-linked
signaling through integrin a5/ITGA5 (Figure 1D; Figure S1C). In
our RNA-seq data from pre-treatment BM CD34+ cells, we
observed that transcription of ITGA5 itself, the receptor for the
extracellular matrix protein fibronectin and a protein known to
be required for maintaining quiescence in HSCs (van der Loo
et al., 1998), was upregulated in AZA non-responders (median
(B) Heatmap indicating the relative differential expression of the 731 genes (in rows) from RNA-seq at pre-treatment between AZA responders (green) and
non-responders (orange). The expression values for each gene have been standardized to have a mean of 0 and an SD of ± 1 across all samples.
(C) Kaplan-Meier survival analysis of an independent cohort of AZA-untreated MDS patients, clustered by k-means based on the differential expression of the
731 genes into putative responders or non-responders, illustrating no significant difference in survival.
(D) IPA of genes upregulated in responders (left) and of genes upregulated in non-responders (right), with the identities of enriched pathways and associated
p values.
(E) Gene set enrichment analysis (GSEA) indicating that cell cycle-related gene sets are enriched in responders compared with non-responders. Normalized
enrichment scores (NESs) and FDR q values are given for the specific gene sets.
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counts per million, non-responders = 1942.8495, responders =
1089.364, q = 2.09E-07; Figure S3C; Table S3). We indepen-
dently validated these findings in pre-treatment CD34+ cells at
both the transcriptional level by qRT-PCR and at the protein level
using flow cytometry (Figure 3A).
To test the effect of blocking ITGA5 in combination with AZA,
we developed a stromal co-culture assay wherein pre-treatment
BMHSPCs from patients were cultured withMS5murine stromal
cells and treated daily with combinations of drugs (as outlined in
Figure 3B). In vivo, response to AZA manifests as improved
hematopoiesis. On this basis, we utilized the capacity to form
colony forming units (CFUs) as an in vitro measure of improved
hematopoietic functionality following combination treatment of
HSPCs from non-responders (Figure 3B). Combination therapy,
utilizing a well-characterized anti-ITGA5-specific antibody
(Nam et al., 2010; Sawada et al., 2008) together with AZA, specif-
ically led to an increase in the total numbers of CFU cells (CFU-
Cs) in three different non-responders (PD7158 and PD7170,
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Figure 2. Increased Cell Cycle Quiescence
Characterizes HPCs of AZA Non-re-
sponders
(A) Hierarchical clustering heatmap of Fluidigm-
basedqRT-PCRmeasurement of the expression of
20 cell cycle-related genes (rows) at pre-treatment
in an independent cohort of AZA-treated patients
(columns). The top bar indicates the patients’ pre-
dicted AZA response based on the hierarchical
clustering (predicted responders in brown, non-
responders in light blue), whereas the bottom bar
indicates the clinically observed response based
on International Working Group (IWG) criteria (AZA
responders in green, non-responders in orange).
Adult BMCD34+ froma healthy individual (yellow in
the bottom bar) is also included as a reference. A
receiver operator characteristic (ROC) curve based
on the expression of the 23 genes per individual is
shown on the right, along with the area under the
curve (AUC) measure.
(B) Representative flow cytometry plots of the cell
cycling status of hematopoietic stem cells (HSCs,
LIN CD34+ CD38low/ CD90+) and HPCs (LIN
CD34+ CD38+) from the BM of a healthy individual,
AZA responder, and AZA non-responder. In each
flow plot, the different cell cycle stages are as fol-
lows: G0 (bottom left quadrant), G1 (top left quad-
rant), and S/G2/M (top right quadrant), with the
percentages of cells in each quadrant indicated.
(C) Boxplots summarizing the proportions of
BM HSCs (top) and HPCs (bottom) in different
stages of the cell cycle in six healthy individuals,
responders and non-responders each. The whis-
kers extend to the maximum and minimum
values, and the median is depicted as a horizontal
bar. Median values for percentages of HSCs in
S/G2/M are indicated above their respective bars.
*p < 0.05 from a two-tailed t test.
CMML; PD7169, MDS; Figure 3C), with
no difference in cell viability (Figure S3C).
In AZA responders, however, there was
no further improvement of CFU-Cs with
combination treatment compared with AZA alone (PD7153 and
PD7155, CMML; PD7168, MDS; Figure 3D). Last, in BM HSPCs
from a healthy individual, we observed no discernible difference
in CFU-Cs between any of the treatment conditions (Figure 3E),
nor any difference in cell viability (Figure S3D). The increase in
CFU-Cs following in vitro combination treatment in AZA non-re-
sponders mirrored what occurs in vivo in AZA responders, with
significantly greater numbers of colonies after six cycles of
AZA treatment (C6d28) compared with pre-treatment (a repre-
sentative responder, PD7165, Figure 3F, and two additional
responders, Figure S3E). Conversely, in vivo in AZA non-re-
sponders undergoing AZA monotherapy, CFU-C numbers
decreased by C6d28 (a representative non-responder, PD7166,
Figure 3F, and two additional non-responders, Figure S3F).
Taken together, these data suggest that upregulated ITGA5
signaling blunts the ability of HSPCs from AZA non-responders
to produceCFUs and that blocking integrin signaling in combina-
tion with AZA improves the functional capability of these cells.
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Figure 3. Targeting Cell Cycle Quiescence by Blocking ITGA5 in CD34+ HSPCs Overcomes AZA Resistance
(A) Upregulation of ITGA5 transcripts in BM CD34+ HSPCs of AZA non-responders compared with responders at pre-treatment, detected at the transcriptional
level by qRT-PCR (left) and at protein level by flow cytometry (right). The mean is depicted as a horizontal bar. *p < 0.05, two-tailed t test.
(B) Schematic depicting the stromal co-culture drug testing setup.
(C) CFU colony counts for pre-treatment BMCD34+HSPCs from three AZA non-responders (PD7170, PD7158, and PD7169) treatedwith vehicle control (control),
500 nM AZA only (AZA), 10 mg/mL anti-ITGA5 antibody only (ITGA5i), or a combination of 500 nM AZA + 10 mg/mL anti-ITGA5 antibody (AZA +ITGA5i) for three
consecutive days in a stromal co-culture. The legend indicates the three different possible types of myeloid colonies (CFU-granulocyte, erythrocyte, monocyte,
megakaryocyte, CFU-GEMM; CFU-granulocyte, monocyte, CFU-GM; BFU, Burst-forming unit) that were observed. *p < 0.05, two-tailed t test.
(legend continued on next page)
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AZA Therapy Induces Pro-inflammatory Pathways
In Vivo in Responders
The mechanisms that determine in vivo effects of response to
AZA therapy are poorly understood. Although a number of previ-
ous studies have assessed the transcriptional response of
in vitro AZA-treated cells (Chiappinelli et al., 2015; Hollenbach
et al., 2010; Karpf et al., 1999; Li et al., 2014; Roulois et al.,
2015), there is a paucity of data available for in vivo response,
especially following the long period (46 months) of treatment
required to see clinical improvements. To address this, we per-
formed RNA-seq analyses on HSPCs from nine responders
and five non-responders at cycle 6 day 28 (C6d28) and
compared gene expression to pre-treatment. GSEAs in re-
sponders identified an upregulation of inflammation-related
genes (Figure 4A; Table S6) at C6d28 compared with pre-treat-
ment. Recently, low-dose AZA treatment in vitro was shown
to induce a set of AZA immune genes (Li et al., 2014). We also
identified a strong enrichment for these genes at C6d28 in vivo
following AZA response (Figure 4B). Orthogonal analyses of
the upregulated genes by IPA also implicated upregulation
of inflammation and immune response pathways following
response to AZA treatment (Figure 4C). In non-responders, how-
ever, we did not observe any alteration of inflammatory path-
ways or of any other specific pathways in general. These findings
provide in vivo evidence to corroborate recent reports that
in vitro AZA treatment of colorectal and ovarian cancer cells
induces inflammatory and immune-related responses through
the induction of intracellular double-stranded RNA (Chiappinelli
et al., 2015; Roulois et al., 2015). Our data suggest that one
of the mechanisms through which AZA therapy effects in vivo
improvement in MDS and CMML patients is through the modu-
lation of inflammatory response pathways.
AZA Alters the Sub-clonal Contribution to Distinct
Hematopoietic Lineages
Although approximately half of all patients will respond to AZA
initially, a response is rarely sustained long-term. A significant
fraction of responders will relapse within a 2-year period of
beginning treatment, with a markedly poor prognosis thereafter
(Pre´bet et al., 2011). The reasons for secondary AZA resistance
are poorly understood and further undermined by a lack of clarity
over the in vivo fate of dysplastic cells upon response to AZA.
By molecularly bar-coding clones using somatic mutations,
we decided to track their fate upon AZA treatment. By exome
sequencing of pre-treatment and C6d28 samples in 16 patients
(Figure S4A), followed by high-depth targeted resequencing
at each time point, including in long-term follow-up samples
(where available), we obtained high-confidence variant allele fre-
quencies (VAFs). Clustering of the VAFs enabled us to distin-
guish different clones. We identified an average of eight muta-
tions per patient (Table S7). Hematopoiesis was clonal in all
patients at pre-treatment, with a single major clone and a
mode of two minor sub-clones per patient (range, one to three
sub-clones), and remained clonal through treatment. In all non-
responders (n = 6), we did not observe any significant changes
in clonal abundance over the course of AZA treatment (Figure 5A;
Figure S4B). These findings are consistent with previous reports
showing that the subclonal structure is unaltered in MDS and
CMML AZA non-responders (Craddock et al., 2013; Itzykson
et al., 2013b). However, even in the majority (n = 8, 80%) of
AZA responders, the clonal mix of MDS cells remained un-
changed even upon complete response, and hematopoiesis
remained fully clonal (Figures 5B–5D; Figure S4C). Only in a
minority of responders (n = 2, 20%) did we observe a diminution
of mutated clones (Figure S4B).
TET2 mutations have been previously correlated with favor-
able AZA response (Bejar et al., 2014a; Itzykson et al., 2011;
Traina et al., 2014), but the fate of mutant clones is unknown.
Four of the six patients with TET2 mutations were responders
(PD7151, PD7153, PD7154, and PD7161). In all patients, the
abundance of the TET2 mutant clones was unchanged with
treatment, indicating that these clones were not eliminated by
AZA treatment (Figure 5C). In PD7153, >85% of the cells in the
BM arose from a clone with two somatic TET2 mutations (TET2
L1065* and TET2 Q685*; Figure 5C). The abundance of the
TET2 clone remained virtually unchanged, even after 2 years of
treatment (Figure 5D). Our data reveal that AZA therapy does
not change the major clonal structure of hematopoiesis in vivo,
even in the event of complete hematologic response. Our find-
ings are consistent with a recent report of the effects of hypome-
thylating therapy on mutant clones in a cohort of CMML patients
(Merlevede et al., 2016).
However, BM VAFs are not informative with respect to he-
matopoietic functionality of resident clones and sub-clones. To
reconcile the persistence of mutant clones with the clinically
observed normalization of hematopoiesis upon AZA response,
we complemented our sequencing analysis of bulk cells with
genotyping of individual CFU colonies to determine clonal contri-
bution to different myeloid lineages (Figure 6A). We designed
custom real-time PCR probes against all identified somatic mu-
tations in two AZA responders (PD7153 and PD7165) and two
non-responders (PD7166 and PD7158) and performed CFU
assays with pre-treatment and C6d28 HSPCs. In PD7153, at
pre-treatment, the colony genotyping data largely reflected the
patterns observed by bulk genotyping; every single colony
contained TET2 drivermutations, and themajority of the colonies
derived from the major clone, with smaller contributions from
the minor subclones (Figure 6B). However, at C6d28, we
observed that a number of colonies that grew up did not contain
the full complement of mutations, but, instead, the clonal contri-
bution to distinct sub-lineages was varied (Figure 6B). Although
all colonies from more primitive granulocyte, erythrocyte,
(D) CFU colony counts for pre-treatment BM CD34+ HSPCs from three AZA responders (PD7153, PD7168, and PD7155) treated with the same four drug
combinations as in (C) for 3 days in stromal co-cultures. *p < 0.05, two-tailed t test. NS, not significant; p > 0.05; two-tailed t test.
(E) CFU colony counts for BMCD34+ HSPCs from a healthy adult treated with the same four drug combinations as in (B) for 3 days in stromal co-cultures. NS, not
significant; p > 0.05; two-tailed t test.
(F) CFU colony counts, per 1,000 BM CD34+ HSPCs plated, from pre-treatment and cycle 6 day 28 (C6d28) BM CD34+ HSPCs from a representative AZA
responder (left) and a non-responder (right). *p < 0.05, two-tailed t test.
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megakaryocyte, macrophage CFU (CFU-GEMM) possessed
the full complement of founder mutations, including both TET2
mutations (Figure 6D), granulocyte macrophage CFU (CFU-
GM) and erythroid burst-forming unit (BFU) colonies were
increasingly derived from cells containing fewer sets of muta-
tions, including just a single TET2 mutation (TET2 p.L1065fs*1,
n = 14, 15%) or two mutations (TET2 p.L1065fs*1, RBPMS2
p.V126L; n = 26; 28%; Figure 6D). Similarly, in another AZA
responder (PD7165), we observed that a number of C6d28
CFU-GM colonies were derived from cells lacking any of the
founder mutations (n = 18, 19%), whereas all pre-treatment
colonies contained a full complement of mutations (Figures
S5A–S5E). No sub-clonal variation was observed in AZA non-
responders (Figure 6C; Figure S5E). Our data indicated that,
although AZA therapy did not completely eliminate dysplastic
clones upon response, it altered the clonal contribution to hema-
topoiesis, enabling previously dormant cloneswith a lowermuta-
tional burden to contribute to hematopoiesis.
DISCUSSION
Although AZA is the most efficacious pharmaceutical option for
MDS and CMML, only about half of the patients will respond.
Given the lack of understanding of themolecular basis of primary
resistance and few therapeutic alternatives, the outcome for AZA
non-responders is poor (Pre´bet et al., 2011). Even among the re-
sponders, the response is rarely sustained, with a poor prog-
nosis thereafter (Fenaux et al., 2009). Although mutation profiling
has recently identified mutations in TET2 and DNMT3A as pre-
dictors of good AZA response (Bejar et al., 2014a; Itzykson
et al., 2011; Traina et al., 2014), they have limited clinical utility
unless better alternative treatment options can be developed
for non-responders.
The present study shows that primary AZA resistance is intri-
cately linked to cell cycle quiescence of HPCs in non-responders
before treatment. Active DNA replication is required for incorpo-
ration of AZA into DNA, enabling the subsequent trapping and
degradation of DNMTs (Stresemann and Lyko, 2008), explaining
why the quiescent cells of non-responders are refractory to
treatment. Our findings are consistent with a recent observation
of increased cell cycle quiescence in CMML non-responders
(Meldi et al., 2015). Of the 61 genes common between our
gene signature and that of Meldi et al. (2015), a large fraction is
related to the cell cycle. By directly measuring cell cycle param-
eters in HSCs and HPCs using flow cytometry, we show that cell
cycle differences between AZA responders and non-responders
are limited to the HPC fraction. Importantly, given that flow cy-
tometry- based cell cycle assessment is performed on unfractio-
nated freeze-thawed BM MNCs, it is more amenable as a diag-
nostic tool than measuring gene expression in fractionated BM
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Figure 4. AZA Therapy Induces Pro-inflammatory Pathways In Vivo in Responders
(A) GSEA plots illustrating strong enrichment for inflammatory and immune response pathways in vivo at C6d28 compared with pre-treatment in AZA responders.
NES and FDR for the gene sets are indicated.
(B) GSEA plot showing enrichment for a previously identified set of immune genes whose expression is induced by AZA treatment (Li et al., 2014).
(C) Significant enrichment for a number of immune- and inflammation-related pathways upregulated in vivo at C6d28 in AZA responders, as identified by IPA.
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Figure 5. Clonal Evolution in the BM of Patients in Response to AZA Therapy
(A) Clonal evolution in the BM of two representative AZA non-responders over the course of treatment. The heatmaps depict the variant allele frequencies for
different somatic mutations (columns; the numbers at the bottom correspond tomutations listed in Table S7) over the entire treatment period (rows). Known driver
mutations previously implicated in cancer or myeloid leukemias are marked in orange in the top bar, whereas mutations of unknown significance are marked in
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(LTFU) where available. The schematic at the bottom of the coxcomb indicates the axes of the different somatic mutations plotted.
(B) Clonal evolution in the BMof two representative AZA responders over the course of treatment. The heatmaps and coxcomb plots are depicted as in (A) at each
of the major treatment time points (including an LTFU sample where available).
(legend continued on next page)
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CD34+ cells. However, our initial discoveries will need to be
further ratified in larger cohorts of patient samples.
Predicting AZA resistance, however, is of limited benefit in the
absence of therapeutic alternatives. An important outcome of
this study is that we provide experimental evidence that AZA
resistance can be overcome by targeting a pathway that is upre-
gulated in AZA non-responders. We have identified that the
increased cell cycle quiescence in AZA non-responders is corre-
lated with the upregulation of ITGA5 and that blocking integrin
signaling in combination with AZA improves the CFU capability
of HSPCs in these patients. Conversely, our results suggest
that combining AZA with drugs that inhibit the cell cycle could
be counterproductive. Indeed, combining histone deacetylase
inhibitors, which are known to inhibit the cell cycle, with AZA
has been the subject of over a decade of clinical testing but
has either failed to show improved efficacy or has been inferior
to AZA alone (Prebet et al., 2014), highlighting the need for
rational data-driven approaches to combination drug therapy.
By bar-coding clones by their mutations, we have identified
that AZA does not alter the abundance of early-arising driver
mutations or clonal hematopoiesis, even upon response. Our
findings are consistent with those of a recent report of the effects
of hypomethylating therapy on mutant clones in a cohort
of CMML patients (Merlevede et al., 2016). However, in the
absence of a functional assessment of persisting clones
following treatment, the basis for restored hematopoiesis
despite the lack of bulk clonal variation in AZA responders re-
mained unresolved in the latter study. By interrogating clonal
function using CFU assays and by performing single-colony gen-
otyping, we show that, although hematopoiesis remains clonal in
responders, AZA therapy significantly changed the sub-clonal
contribution to distinct hematopoietic lineages. Although clones
with a highmutation burden were present at all stages of myeloid
differentiation (CFU-GEMM, CFU-GM, and BFU) before treat-
ment, AZA treatment appears to specifically blunt the ability of
these clones to become more lineage-committed cells (CFU-
GM and BFU; Figure 6E). Instead, cells bearing fewer mutations
are more abundantly detected in these populations. We specu-
late that the more mutated cells have a clonal advantage,
enabling them to populate more of the BM, preferentially at
pre-treatment, but are also less capable of differentiating nor-
mally. AZA prevents clones with a high mutational burden from
crowding out less mutated cells that are more capable of differ-
entiating normally, thereby improving hematopoiesis (Figure 6E).
However, there are caveats to our findings that necessitate
further study; First, given the small number of patients in
our cohort, although extensively interrogated molecularly, our
discoveries warrant validation in larger sets of patients.
Also, because we performed exome sequencing using DNA
from BM MNCs with some differentiation potential, we cannot
exclude the possibility that there are other clones bearing further
mutations that are completely incapable of differentiation. Addi-
tionally, given that clonal hematopoiesis is frequently observed
in aging (Busque et al., 2012), albeit with an increased risk of
acquiring hematological malignancy (Genovese et al., 2014;
Jaiswal et al., 2014; Xie et al., 2014), it is possible that some of
the clonal hematopoiesis observed upon AZA response may
not have accompanying dysplasia. Indeed, the association be-
tween specific mutations and marrow dysplasia warrants further
investigation, given the current uncertainty over the distinction
between clonal hematopoiesis of indeterminate potential and
myelodysplastic syndromes (Steensma et al., 2015).
Last, we find in vivo evidence to support that AZA therapy in-
duces inflammatory- and immune-related responses in HSPCs
of AZA responders, consistent with recent work in solid tumor
cell lines (Chiappinelli et al., 2015; Roulois et al., 2015). Taken
together with our clonal evolution and functional data, these find-
ings suggest that the induction of pro-inflammatory pathways in
persisting dysplastic clones by AZA facilitates their contribution
toward functional hematopoiesis in vivo, a clinical hallmark of
AZA response.
Therefore by utilizing primary patient material from well anno-
tated treatment cohorts and by integrating transcriptomics, ge-
nomics, and clonal function, we provide insights into the molec-
ular basis of primary AZA resistance, mechanisms to predict and
overcome AZA resistance, and evidence for clonal hematopoie-
sis in the presence of persistent, highly mutated MDS/CMML
HSPCs in complete responders. These findings should serve
as a platform for more effective utilization of AZA and develop-
ment of more durable therapies for treating MDS and CMML.
EXPERIMENTAL PROCEDURES
Patients and Sample Collections
Nineteen individuals (seven females and 12 males) aged 59–88 with MDS or
CMML (Table S1) were recruited from New South Wales, Australia on a
compassionate access basis for AZA. All samples were obtained with written
informed consent in accordance with the Declaration of Helsinki and approval
of the human research ethics committee of the South Eastern Sydney Local
Health District. BM samples were collected from each individual at defined
time points. Immediately upon sample collection, MNCs were isolated from
the BM by density centrifugation using Lymphoprep (STEMCELL Technolo-
gies). Approximately 2 3 108 MNCs per sample were then incubated with
CD34+ magnetic beads (Miltenyi Biotec) and separated using an AutoMACS
Pro machine (Miltenyi Biotec) exactly as recommended by the manufacturer.
Approximately 1 3105 CD34+ and CD34 cells were used to prepare RNA
(CD34+) and DNA (CD34+, CD34). All remaining cells (MNCs, CD34+, and
CD34) were frozen viably and stored to be used later in functional assays
or for flow cytometry as necessary. Details are described in the Supplemental
Experimental Procedures.
Transcriptomic Analyses
Total RNA was amplified using the Ovation RNA-seq System v2 kit (NuGEN)
prior to RNA-seq. Approximately 1 mg of the resulting, amplified, double-
stranded cDNA was fragmented and used to prepare 90-bp paired-end
sequencing libraries using the TruSeq RNA library preparation kit (Illumina)
according to the manufacturer’s recommendations. All sequencing was
(C) Clonal evolution in the BM of AZA responders with TET2 mutations. In individuals with multiple TET2 mutations (PD7151 and PD7153), the location of the
mutations (columns) in the heatmap are indicated with differently shaded arrowheads. The coxcomb plots indicate the VAFs for the TET2 mutations across the
course of AZA treatment, going clockwise from pre-treatment to LTFU.
(D) Coxcomb plots illustrating VAFs of all identified somatic mutations in the BM of AZA responder PD7153 at every point during the entire course of treatment.
The arrowheads indicate the two TET2 mutant alleles.
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Figure 6. AZA Alters the Sub-clonal Contribution to Distinct Hematopoietic Lineages
(A) Schematic of CFU genotyping.
(B) Heatmap representation of Fluidigm-based genotyping of individual CFU-Cs (columns) at pre-treatment and C6d28 from AZA responder PD7153. The
homozygous wild-type allele at any locus is shaded in blue, the heterozygous allele is shaded in orange, and the homozygous mutant allele is shaded in red. The
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(C) Fluidigm-based genotyping of individual CFU-Cs from an AZA non-responder (PD7166).
(D) Genotypes of different colony types from PD7153 based on the cell of origin.
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performed on a Hiseq2000 sequencer (Illumina) at BGI. Cleaned raw
sequencing reads were aligned individually against the human genome refer-
ence (hg19) using TopHat (version 2.0.4) (Kim et al., 2013) with default param-
eters. Gene level expression was quantified using the DESeq2 (version 1.10.1)
(Love et al., 2014) package in R. The quartiles of genes with the lowest counts
were filtered, followed by standard normalization procedures for the read sets
across the samples. A full description of the methods is available in the Sup-
plemental Experimental Procedures. Fluidigm analyses for gene expression
were performed using dynamic arrays on the BioMark HD (Fluidigm). Details
are described in the Supplemental Experimental Procedures.
Cell Cycle Assessment of BM Cells by Flow Cytometry
Assessment of the cell cycle within defined sub-populations of unfractionated
BM MNCs was performed using an adaptation of a previously established
method (Tehranchi et al., 2010). Details are described in the Supplemental
Experimental Procedures.
CFU Assays and Colony Genotyping
Clonogenic progenitors were quantified in triplicate by their property to form
colonies in 1% methylcellulose (Fluka) supplemented with cytokines at 37C
in 5% CO2 as described previously (MacKenzie et al., 2000). BM CD34
+
HSPCs from healthy individuals (controls) or MDS or CMML patients were
plated in 35-cm tissue culture dishes (BD Falcon) at 500 cells/dish (healthy
or CMML individuals) or 1,000 cells/dish (MDS patients), respectively. CFU-
GMs, CFU-GEMMs, and BFUs were scored after 14 days of culture using an
invertedmicroscope. Individual CFU colonies were scored by visual identifica-
tion under a dissection microscope, 96 individual colonies from each treat-
ment point (pre-treatment and C6d28) were plucked using a micropipette,
and genomic DNA was extracted from the pellet using the TaqMan Sample-
to-SNP Kit (Thermo Scientific) following the manufacturer’s recommenda-
tions. Approximately 1.2 mL of lysate from each colony was then used for gen-
otyping using custom-designed SNPtype assays (Fluidigm) against individual
somatic mutations identified in each patient. Details are described in the Sup-
plemental Experimental Procedures.
Stromal Co-culture and Drug Testing
Drug testing in vitro was performed using primary pre-treatment BM CD34+
HSPCs from patients co-cultured with murine stromal MS5 cells. A confluent
monolayer of MS5 cells was pre-seeded in 24-well plates at least 24 hr prior
to the addition of CD34+ HSPCs. The stromal co-cultures were done in dupli-
cate; one set of cells was used for subsequent CFU assays, whereas the
other set was used for flow cytometry assays to determine viability and cell
number. Drugs and media were changed daily to account for the short half-
life of the drugs in aqueous solution. CFU assays were performed as
described above. For determination of cell viability and cell numbers by
flow cytometry, the entire contents of a well were recovered by trypsinization,
followed by washes with PBS. Details are described in the Supplemental
Experimental Procedures.
Exome Sequencing
Whole-exome sequencing and data analysis were performed on pre-treatment
and C6d28 samples, essentially as described previously (Papaemmanuil et al.,
2013). Genomic DNA was prepared from BM CD34 cells from patients at all
time points and whole-genome amplified using Phi29 (QIAGEN). Additionally,
DNA was prepared from buccal swabs collected from the individuals at pre-
treatment using the QIAamp DNA mini kit (QIAGEN) and used as a germline
control to identify somatically acquired mutations in each individual. Exome
enrichment was performed using the SureSelect Human All Exon kit (Agilent
Technologies) following the manufacturer’s guidelines. Details are described
in the Supplemental Experimental Procedures.
Statistical Analyses
All statistical analyses on clinical parameters were performed in R. Fisher’s
exact t test (for disease type, gender, and cytogenetics), log rank (Mantel-
Cox) test for survival analyses, two-tailed, unpaired Student’s t test (for
normally distributed data), and Wilcoxon signed-rank test (for non-normally
distributed data) were performed where appropriate. Statistical correlations
between the gene signature and clinical parameters were done by logistic
regression using the glm package in R. Significance was considered for
p < 0.05. FDRs for RNA-seq analyses were generated using DESeq2
(version 1.10.1) (Love et al., 2014). Receiver operator characteristic (ROC)
analyses were performed in GraphPad Prism v6.0 (GraphPad). Details of
the respective tests are described in full in the Supplemental Experimental
Procedures.
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The accession number for the sequencing data reported in this paper is GEO:
GSE76203.
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